Inclusion Criteria:

          -  Histologically or cytologically confirmed prostate adenocarcinoma in the very low or
             low risk risk stratification groups (i.e. Grade group 1 or Gleason score ≤ 6) and
             eligible for radiation therapy.

          -  Ability to receive prostatic artery embolization within 6-12 weeks of definitive
             radiation therapy.

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Prostate larger than 60 grams but less than 150 grams, as assessed by imaging scans

          -  American Urologic Association (AUA) or International Prostate Symptom Score (IPSS)
             Score ≥ 15

          -  Normal organ and marrow function as defined in protocol

        Exclusion Criteria:

          -  Receiving androgen deprivation therapy (ADT)

          -  Patients with intermediate or high risk localized PCa (Gleason Grade Groups 4 and 5)

          -  Receiving any investigational agents for the explicit purpose of prostatic size
             reduction

          -  Inability to receive prostatic artery embolization (PAE) within 6-12 weeks of
             definitive radiation therapy

          -  Active urinary tract infection (UTI)

          -  History of severe allergic reaction to intravenous contrast media (iodinated and
             gadolinium- based) or any agents used during the PAE; patient cannot be medicated
             against allergic reaction prior to PAE.

          -  Active cystolithiasis or prostatitis

          -  Inability to have multi-parametric magnetic resonance imaging (mpMRI)

          -  Prior transurethral resection of the prostate (TURP) within 2 years

          -  Prostate size greater than 150 grams

          -  Vulnerable subjects (e.g., inmates and developmentally delayed adults) who are
             subjects for whom the study may be unsafe or whose rights may be violated with
             enrollment.